H5N1c
Biological
Seqirus USA Inc
Total Payments
$2.5M
Transactions
72
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $2.5M | 72 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 72 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate Safety Immunogenicity and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects greater than or equal to 18 Years of Age | Seqirus USA Inc | $2.5M | 0 |
| A Phase III Randomized Observer-Blind Controlled Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults greater than or equal to 65 Years of Age | Seqirus USA Inc | $9,200 | 0 |
Top Doctors Receiving Payments for H5N1c
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rockville, MD | $2.5M | 72 |
Ad
Manufacturing Companies
- Seqirus USA Inc $2.5M
Product Information
- Type Biological
- Total Payments $2.5M
- Total Doctors 0
- Transactions 72
About H5N1c
H5N1c is a biological associated with $2.5M in payments to 0 healthcare providers, recorded across 72 transactions in the CMS Open Payments database. The primary manufacturer is Seqirus USA Inc.
Payment data is available from 2017 to 2017. In 2017, $2.5M was paid across 72 transactions to 0 doctors.
The most common payment nature for H5N1c is "Unspecified" ($2.5M, 100.0% of total).
H5N1c is associated with 2 research studies, including "A Study to Evaluate Safety Immunogenicity and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects greater than or equal to 18 Years of Age" ($2.5M).